ANTOLRX
At AnTolRx they are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors. Thus, there is an unmet clinical need for methods of targeted immune-regulation. Their proprietary drug development approach selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.
ANTOLRX
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.antolrx.com
Total Employee:
11+
Status:
Active
Contact:
(617)945-8468
Email Addresses:
[email protected]
Total Funding:
4 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Font API Google Tag Manager WordPress Google Analytics SSL By Default Global Site Tag
Similar Organizations
Crown Bioscience
CrownBio is helping provide clarity of action in the fight against cancer and diabetes.
Idenix Pharmaceuticals
Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Proclara Biosciences
Proclara is pioneering a new approach to treating neurodegenerative diseases.
Patara Pharma
Patara Pharma operates in the healthcare industry focusing on the biotechnology business.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
VLP Therapeutics
VLP is a biotech company with a mission to address unmet medical needs worldwide and expand the frontiers of vaccine treatment.
Current Advisors List
Current Employees Featured
Founder
Investors List
JDRF (The Juvenile Diabetes Research Foundation)
JDRF (The Juvenile Diabetes Research Foundation) investment in Series A - AnTolRx
Orion Healthcare Equity Partners
Orion Healthcare Equity Partners investment in Series A - AnTolRx
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - AnTolRx
Official Site Inspections
http://www.antolrx.com Semrush global rank: 9.08 M Semrush visits lastest month: 445
- Host name: swh01.ttlc.com
- IP address: 66.94.40.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AnTolRx"
AnTolRx - Crunchbase Company Profile & Funding
At AnTolRx they are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to …See details»
ANTOLRX | Antigen Tolerance Pharmaceuticals
Dec 15, 2020 AnTolRx’s vision is to build a platform that selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and …See details»
Team - ANTOLRX
AnTolRx is led by an experienced and knowledgeable team of scientists, advisors, board members and partners dedicated to developing new therapeutics and advancing the field of immunotherapy. AnTolRx was founded based on …See details»
ANTOLRX ANNOUNCES PFIZER EXERCISES OPTION TO LICENSE …
Mar 5, 2019 AnTolRx, Inc. was founded in 2016 by Professor Francisco Quintana, Dr. Satish Jindal and Mark Carthy with initial equity investment from Pfizer Inc., JDRF International and …See details»
AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF …
CAMBRIDGE, Mass., September 8, 2016—AnTolRx, Inc. announced today that it has signed a Series A funding agreement with Pfizer Inc. (NYSE: PFE), Orion Equity Partners LLC and …See details»
AnTolRx - Headquarter Location, Corporate Office Address and …
AnTolRx is Drug Discovery in United States that focus on drug development approach business. Founded in 2015. They cover business area such as developer, novel nanoformulation-base …See details»
AnTolRx 2025 Company Profile: Valuation, Funding
AnTolRx General Information Description. Developer of novel nanoformulation-based therapies designed to treat autoimmune diseases. The company's drug development approach selectively targets pathogenic immune cells providing …See details»
Antolrx, Inc. Company Profile | Cambridge, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AntolRx, Inc. of Belmont, MA. Get the latest business insights from Dun & Bradstreet.See details»
AnTolRx Company Profile - Office Locations, Competitors ... - Craft
AnTolRx is a biotech company focused on the treatment of autoimmune diseases. Its lead programs address unmet needs in the fields of type 1 diabetes, rheumatoid arthritis, …See details»
Antolrx - Overview, News & Similar companies | ZoomInfo.com
Mar 4, 2019 Who is Antolrx. AnTolRx is a Cambridge, Mass.-based research and development biotechnology company focused on immune tolerance with active programs in Type 1 Diabe …See details»
AnTolRx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore AnTolRx, Inc. with its drug pipeline, therapeutic area, technology platform, 1 literature, Disease Domain:Immune System Diseases, Endocrinology and Metabolic Disease, Nervous …See details»
AnTolRx - Products, Competitors, Financials, Employees, …
AnTolRx, Diabeloop, IPaDiC, Encellin & POLTREG develop 5 top solutions to watch out for. Our Innovation Analysts recently looked into emerging technologies and up-and-coming startups …See details»
AnTolRx - Funding, Financials, Valuation & Investors - Crunchbase
AnTolRx is funded by 3 investors. JDRF (The Juvenile Diabetes Research Foundation) and Orion Healthcare Equity Partners are the most recent investors. AnTolRx has a post-money …See details»
AnTolRx, Inc. Announces Series A Equity Funding from Pfizer,
CAMBRIDGE, Mass., September 8, 2016—AnTolRx, Inc. announced today that it has signed a Series A funding agreement with Pfizer Inc. (NYSE: PFE), Orion Equity Partners LLC and …See details»
AnTolRx, Inc. - T1D Fund: A Breakthrough T1D Venture
AnTolRx, Inc. About The T1D Fund. The T1D Fund is a venture philanthropy fund accelerating life-changing solutions to treat, prevent, and ultimately cure T1D. Launched in December …See details»
Pipeline - ANTOLRX
We are rapidly advancing a potential therapy for the treatment of Type 1 Diabetes and are advancing pre-clinical programs in a number of other auto-immune related diseases, including …See details»
Pfizer licenses AnTolRx's immune tolerance nanomedicine for Type …
Mar 5, 2019 Back in 2016, Pfizer led a $4 million round for AnTolRx to fund the research and development of its antigen-specific immune tolerance treatment for diabetes. Now, the Big …See details»
Pfizer Licenses AnTolRx Type 1 Diabetes Candidate - Pharma's …
Mar 12, 2019 Pfizer has elected to exercise an option it was granted in a June 2016 agreement to license the AnTolRx's lead candidate in type 1 diabetes. Pfizer will pay AnTolRx an up-front …See details»
News - ANTOLRX
Oct 29, 2019 CAMBRIDGE, Mass., September 8, 2016—AnTolRx, Inc. announced today that it has signed a Series A funding agreement with Pfizer Inc. (NYSE: PFE), Orion Equity Partners …See details»
Our Vision | ANTOLRX
At AnTolRx we are approaching the treatment of autoimmune diseases differently–through the development of novel nanoformulation-based therapies to promote antigen-specific immune …See details»